文章摘要
朱颖炜,龚 镭,吴高珏,胥 明,胡 臻,唐学军,彭晓斌,张丽莉.超声内镜引导下瘤体内注射H101治疗胰腺癌疗效分析[J].南京医科大学学报,2016,(10):1166~1169,1187
超声内镜引导下瘤体内注射H101治疗胰腺癌疗效分析
Therapeutic effects analysis of tumor injection of H101 guided by endoscopic ultrasonography for patients with pancreatic carcinoma
投稿时间:2016-03-28  
DOI:10.7655/NYDXBNS20161004
中文关键词: 超声内镜  瘤体内注射  H101  胰腺癌  疗效
英文关键词: endoscopic ultrasonography  tumor injection  H101  pancreatic carcinoma  therapeutic effects
基金项目:无锡市科技局指令性项目(CSE01N1217)
作者单位
朱颖炜 南京医科大学附属无锡第二医院消化内科,江苏 无锡 214002 
龚 镭 南京医科大学附属无锡第二医院消化内科,江苏 无锡 214002 
吴高珏 南京医科大学附属无锡第二医院消化内科,江苏 无锡 214002 
胥 明 上海东方医院消化内科,上海 200120 
胡 臻 南京医科大学附属无锡第二医院消化内科,江苏 无锡 214002 
唐学军 南京医科大学附属无锡第二医院消化内科,江苏 无锡 214002 
彭晓斌 南京医科大学附属无锡第二医院消化内科,江苏 无锡 214002 
张丽莉 南京医科大学附属无锡第二医院消化内科,江苏 无锡 214002 
摘要点击次数: 585
全文下载次数: 389
中文摘要:
      目的:探讨超声内镜(endoscopic ultrasonography,EUS)引导下瘤体内注射H101治疗胰腺癌的方法及疗效。方法:92例中晚期胰腺癌根据意愿分为H101组(n=40)及化疗组(n=52)。其中H101组给予EUS引导下瘤体内注射H101联合吉西他滨治疗,化疗组给予静脉注射吉西他滨单药化疗。分析治疗后瘤体变化?KPS及VAS评分?生存分析及治疗不良反应。结果:H101组治疗4?12个月后部分缓解(PR)率及有效率(40.0%,62.5%)均显著高于化疗组(16.7%,20.0%)(P < 0.05)。H101组及化疗组12个月内存活患者KPS评分在治疗4?8?12个月后均较治疗前显著升高(P < 0.05),VAS评分均显著降低(P < 0.05),而2组之间相比各时间点VAS及KPS评分均无显著差异(P > 0.05)。H101组12个月内病死率(60.0%)较化疗组(80.8%)显著降低(χ2=4.810,P=0.028)。H101组中位生存期为(8.8 ± 0.5)个月(95%CI:7.87~9.68),较化疗组(7.6 ± 0.4)个月显著延长(χ2=3.976,P=0.046)。结论:EUS引导下瘤体内注射H101联合吉西他滨治疗中晚期胰腺癌是安全有效的,有助于提高患者生存质量?延长生存期。
英文摘要:
      Objective:To explore the methods and effects of tumor injection of H101 guided by endoscopic ultrasonography(EUS)for patients with pancreatic carcinoma. Methods:A total of 92 patients with advanced pancreatic carcinoma were divided into the H101 group(n=40) and the chemotherapy group(n=52). The patients in the H101 group were treated by tumor injection of H101 guided by EUS complicated with gemcitabine and the patients in the chemotherapy group were treated only by gemcitabine. The changes of tumor body,VAS and KPS score,survival analysis,and adverse reaction were analyzed. Results:The partial remission (PR)rate and effective rate of the H101 group(40.0%,62.5%) was higher than those of the chemotherapy group (16.7%,20.0%) after 4,12 months of treatment(P < 0.05). The KPS score was elevated after 4,8 and 12 months of treatment and VAS score was decreased(P < 0.05),but there was no difference in the two groups(P > 0.05). The mortality of the H101 group (60.0%) in 12 months was decreased than that of the chemotherapy group(80.8%)(χ2=4.810,P=0.028). The mid-life span of the H101 group was(8.8 ± 0.5) months and prolonged than that of the chemotherapy group [(7.6 ± 0.4)months,χ2=3.976,P=0.046]. Conclusion:Tumor injection of H101 guided by EUS is safe and feasible for patients with advanced pancreatic carcinoma,and is helpful to improve the life quality and prolong life span.
查看全文   查看/发表评论  下载PDF阅读器
关闭